YS Biopharma Co., Ltd. (NASDAQ:YS - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $6.82 and last traded at $6.82, with a volume of 0 shares trading hands. The stock had previously closed at $6.82.
YS Biopharma Stock Performance
The business has a 50-day moving average of $0.53 and a two-hundred day moving average of $0.67. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.73 and a current ratio of 0.94.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in YS Biopharma stock. Superstring Capital Management LP bought a new stake in shares of YS Biopharma Co., Ltd. (NASDAQ:YS - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 307,920 shares of the company's stock, valued at approximately $166,000. Superstring Capital Management LP owned about 0.33% of YS Biopharma as of its most recent filing with the SEC. 52.64% of the stock is currently owned by institutional investors.
About YS Biopharma
(
Get Free Report)
YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider YS Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and YS Biopharma wasn't on the list.
While YS Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
